| 000 | 01920 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517112310.0 | ||
| 264 | 0 | _c20180209 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1557-3265 | ||
| 024 | 7 |
_a10.1158/1078-0432.CCR-16-1207 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKelly, Kevin | |
| 245 | 0 | 0 |
_aSafety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. _h[electronic resource] |
| 260 |
_bClinical cancer research : an official journal of the American Association for Cancer Research _cMar 2017 |
||
| 300 |
_a1186-1192 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAminopyridines _xadministration & dosage |
| 650 | 0 | 4 |
_aB-Lymphocytes _xdrug effects |
| 650 | 0 | 4 |
_aBenzamides _xadministration & dosage |
| 650 | 0 | 4 |
_aCyclic Nucleotide Phosphodiesterases, Type 4 _xdrug effects |
| 650 | 0 | 4 |
_aCyclopropanes _xadministration & dosage |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xpathology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPhosphatidylinositol 3-Kinases _xgenetics |
| 650 | 0 | 4 |
_aPhosphodiesterase 4 Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aPhosphoinositide-3 Kinase Inhibitors |
| 700 | 1 | _aMejia, Alex | |
| 700 | 1 | _aSuhasini, Avvaru N | |
| 700 | 1 | _aLin, An-Ping | |
| 700 | 1 | _aKuhn, John | |
| 700 | 1 | _aKarnad, Anand B | |
| 700 | 1 | _aWeitman, Steven | |
| 700 | 1 | _aAguiar, Ricardo C T | |
| 773 | 0 |
_tClinical cancer research : an official journal of the American Association for Cancer Research _gvol. 23 _gno. 5 _gp. 1186-1192 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1078-0432.CCR-16-1207 _zAvailable from publisher's website |
| 999 |
_c26344135 _d26344135 |
||